Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of short-term operating activity ratios reveals several noteworthy trends between 2021 and 2025. Generally, the period demonstrates fluctuations in efficiency metrics, with some indicators suggesting improved performance in certain years, offset by declines in others. Overall, the company appears to be managing its short-term assets and liabilities with some inconsistency over the five-year span.
- Inventory Management
- Inventory turnover exhibited a slight downward trend from 4.16 in 2021 to 3.80 in 2023, before recovering to 4.15 in 2024 and slightly declining again to 4.04 in 2025. This suggests a minor decrease in the speed at which inventory is sold and replenished, followed by a partial recovery. Correspondingly, the average inventory processing period increased from 88 days in 2021 to a peak of 96 days in 2023, then decreased to 88 days in 2024 and increased slightly to 90 days in 2025. This mirrors the inventory turnover trend, indicating inventory is taking slightly longer to convert into sales.
- Receivables Management
- Receivables turnover remained relatively stable between 2021 and 2023, fluctuating around 6.3. A notable increase to 6.75 was observed in 2024, followed by a decrease to 6.28 in 2025. The average receivable collection period remained consistent at 57 days for 2021, 2022, and 2023, decreased to 54 days in 2024, and then increased to 58 days in 2025. These movements suggest a generally efficient collection of receivables, with a temporary improvement in 2024.
- Payables Management
- Payables turnover increased from 4.48 in 2021 to 5.58 in 2023, indicating a faster rate of paying suppliers. It then stabilized around 5.5 for 2024 and 2025. The average payables payment period decreased from 82 days in 2021 to 65-67 days between 2022 and 2024, and remained at 67 days in 2025. This suggests the company has been effectively shortening the time taken to settle its obligations to suppliers.
- Overall Operating Cycle & Cash Conversion Cycle
- The operating cycle lengthened from 145 days in 2021 to 156 days in 2023, before decreasing to 142 days in 2024 and increasing to 148 days in 2025. The cash conversion cycle experienced a more pronounced increase, rising from 63 days in 2021 to 91 days in 2023, then decreasing to 76 days in 2024 and increasing to 81 days in 2025. The increase in the cash conversion cycle, particularly in 2023, suggests a longer period between paying for inventory and collecting cash from sales, potentially indicating a need for improved working capital management.
- Working Capital Turnover
- Working capital turnover demonstrated significant volatility. It decreased sharply from 8.40 in 2021 to 4.20 in 2022 and remained at 4.22 in 2023, before increasing substantially to 8.85 in 2024 and decreasing to 4.13 in 2025. This suggests considerable fluctuations in the efficiency with which working capital is used to generate sales, with a particularly strong performance in 2024 followed by a return to lower levels in 2025.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | ||||||
| Inventories | ||||||
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | ||||||
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Inventory Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of sales ÷ Inventories
= ÷ =
2 Click competitor name to see calculations.
The analysis reveals fluctuations in inventory turnover over the five-year period. While generally remaining within a narrow range, observable shifts warrant consideration. Cost of sales experienced an initial increase followed by a decline, while inventory levels also demonstrated variability.
- Inventory Turnover
- The inventory turnover ratio decreased from 4.16 in 2021 to 4.03 in 2022, representing a slight reduction in the efficiency of inventory management. A further decrease to 3.80 was noted in 2023, indicating a slower rate of inventory conversion into sales. The ratio then rebounded to 4.15 in 2024, suggesting improved inventory management practices or increased demand. Finally, the ratio settled at 4.04 in 2025, remaining near the level observed in 2021 and 2022.
- Cost of Sales
- Cost of sales increased from US$11,501 million in 2021 to US$12,522 million in 2022, potentially driven by increased production volume or higher input costs. However, a subsequent decline to US$9,856 million in 2023 was observed, possibly due to reduced sales or improved cost control measures. Cost of sales remained relatively stable at US$9,669 million in 2024 and increased slightly to US$10,045 million in 2025.
- Inventories
- Inventory levels increased from US$2,767 million in 2021 to US$3,110 million in 2022, potentially indicating anticipation of higher future sales or supply chain disruptions. A decrease to US$2,594 million in 2023 was recorded, followed by a further reduction to US$2,330 million in 2024. Inventory levels then increased modestly to US$2,489 million in 2025.
The interplay between cost of sales and inventory levels appears to influence the inventory turnover ratio. The decrease in turnover in 2023 coincided with both a decrease in cost of sales and a decrease in inventories, but the decline in cost of sales was proportionally larger. The subsequent increase in turnover in 2024 suggests a more effective balance between sales and inventory management.
Receivables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Sales | ||||||
| Trade accounts receivable, less allowance for doubtful accounts | ||||||
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | ||||||
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Receivables Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Sales ÷ Trade accounts receivable, less allowance for doubtful accounts
= ÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibited a generally stable pattern over the five-year period, with some fluctuation. Sales experienced an initial increase followed by a decline and subsequent stabilization. Accounts receivable mirrored this trend, though with less pronounced changes.
- Receivables Turnover Trend
- The receivables turnover ratio began at 6.36 in 2021 and slightly increased to 6.40 in 2022. A minor decrease to 6.09 was observed in 2023, coinciding with a significant reduction in sales. The ratio then rose to its highest point of 6.75 in 2024, despite sales remaining relatively constant. Finally, the ratio decreased slightly to 6.28 in 2025.
- Sales and Receivables Relationship
- Sales increased from US$29,453 million in 2021 to US$31,471 million in 2022, while trade accounts receivable also increased from US$4,631 million to US$4,918 million. The subsequent decline in sales to US$23,890 million in 2023 was accompanied by a decrease in trade accounts receivable to US$3,922 million. Trade accounts receivable continued to decrease to US$3,537 million in 2024, and then increased to US$3,913 million in 2025, while sales remained relatively stable.
- Overall Interpretation
- The consistent receivables turnover ratio suggests a stable credit and collection policy throughout the period. The increase in the ratio in 2024, despite flat sales, may indicate improved efficiency in collecting receivables. The slight decrease in 2025 warrants further investigation, but does not appear to represent a significant shift in the company’s ability to convert receivables into cash.
The observed fluctuations in receivables turnover generally align with changes in sales volume, indicating a predictable relationship between revenue generation and the speed at which receivables are collected.
Payables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | ||||||
| Trade accounts payable | ||||||
| Short-term Activity Ratio | ||||||
| Payables turnover1 | ||||||
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Payables Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of sales ÷ Trade accounts payable
= ÷ =
2 Click competitor name to see calculations.
The analysis of payables turnover reveals a generally stable, yet subtly shifting, pattern over the five-year period. Cost of sales experienced fluctuation, while trade accounts payable demonstrated a consistent downward trend before stabilizing. This interplay significantly influences the observed payables turnover ratio.
- Payables Turnover
- The payables turnover ratio exhibited an initial increase from 4.48 in 2021 to 5.45 in 2022, indicating a more efficient use of credit terms with suppliers. This improvement suggests the company was paying its suppliers more quickly. The ratio continued to rise, reaching 5.58 in 2023. Subsequently, a slight decrease to 5.52 was observed in 2024, followed by a further decline to 5.45 in 2025. While these later decreases are minor, they suggest a potential easing of payment speed or a relative increase in accounts payable.
- Cost of Sales
- Cost of sales increased from US$11,501 million in 2021 to US$12,522 million in 2022, reflecting increased operational activity. A notable decrease occurred in 2023, with cost of sales falling to US$9,856 million. This decline continued into 2024, reaching US$9,669 million, before a modest recovery to US$10,045 million in 2025. These fluctuations in cost of sales, when considered alongside the payables turnover, provide a more nuanced understanding of the company’s purchasing and payment practices.
- Trade Accounts Payable
- Trade accounts payable consistently decreased from US$2,569 million in 2021 to US$1,753 million in 2024. This suggests a strengthening of the company’s negotiating position with suppliers, improved inventory management, or a deliberate strategy to reduce liabilities. A slight increase to US$1,844 million was recorded in 2025, potentially indicating a reversal of this trend or a seasonal increase in purchasing activity.
The combination of decreasing payables and fluctuating cost of sales resulted in the observed payables turnover pattern. The initial increase in turnover coincided with both rising cost of sales and decreasing payables. The subsequent stabilization and slight decline in turnover occurred despite relatively stable payables in the last two years, suggesting the fluctuations in cost of sales were the primary driver of the recent changes in the ratio.
Working Capital Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | ||||||
| Less: Current liabilities | ||||||
| Working capital | ||||||
| Sales | ||||||
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | ||||||
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Working Capital Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Sales ÷ Working capital
= ÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibits considerable fluctuation over the five-year period. Initial values demonstrate a substantial decline followed by a period of relative stability and then another significant shift. This suggests potential changes in the company’s operational efficiency or working capital management strategies.
- Working Capital
- Working capital levels increased significantly from 2021 to 2022, more than doubling. A subsequent decrease occurred in 2023, followed by a further reduction in 2024, reaching the lowest point in the observed period. An increase is then noted in 2025, though not reaching the 2022 peak. These fluctuations indicate varying levels of short-term assets and liabilities.
- Sales
- Sales experienced a moderate increase between 2021 and 2022. However, a substantial decrease was observed in 2023, with sales remaining relatively stable in 2024. A slight increase in sales is recorded for 2025, but it does not fully recover to the 2021 or 2022 levels.
- Working Capital Turnover
- The working capital turnover ratio began at 8.40 in 2021, indicating efficient utilization of working capital to generate sales. A sharp decline to 4.20 occurred in 2022, coinciding with the substantial increase in working capital and a smaller increase in sales. The ratio remained relatively stable at 4.22 in 2023. A notable increase to 8.85 was observed in 2024, driven by a significant decrease in working capital while sales remained consistent. The ratio then decreased again in 2025 to 4.13, aligning with the increase in working capital.
- The observed pattern suggests that changes in the ratio are more strongly influenced by fluctuations in working capital than by changes in sales. The high turnover in 2021 and 2024 suggests periods of efficient working capital management, while the lower ratios in 2022, 2023, and 2025 may indicate either less efficient utilization or a strategic decision to hold higher levels of working capital.
Overall, the analysis reveals a dynamic relationship between working capital, sales, and the resulting turnover ratio. Further investigation into the underlying drivers of these fluctuations would be necessary to determine the effectiveness of the company’s working capital management practices.
Average Inventory Processing Period
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Inventory Processing Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The period under review demonstrates fluctuations in inventory management efficiency. Analysis focuses on the inventory turnover ratio and the average inventory processing period, revealing a complex pattern of performance.
- Inventory Turnover
- The inventory turnover ratio experienced a slight decline from 4.16 in 2021 to 4.03 in 2022. This downward trend continued into 2023, with the ratio reaching 3.80. A subsequent increase was observed in 2024, returning to 4.15, before settling at 4.04 in 2025. This suggests periods of both efficient and less efficient inventory management, with a recent stabilization.
- Average Inventory Processing Period
- The average inventory processing period exhibited an increasing trend from 88 days in 2021 to 96 days in 2023. This indicates a lengthening of the time required to convert inventory into sales. However, the period decreased to 88 days in 2024, mirroring the improvement in the inventory turnover ratio. A slight increase to 90 days was noted in 2025. The fluctuations suggest potential responsiveness to market conditions or internal operational changes.
The observed trends indicate an inverse relationship between the inventory turnover ratio and the average inventory processing period. When turnover decreased, the processing period increased, and vice versa. The return to prior levels in 2024 for both metrics suggests a potential correction of inefficiencies experienced in 2023. The slight increase in the processing period in 2025 warrants continued monitoring to determine if it signals a renewed trend.
Average Receivable Collection Period
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Receivable Collection Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited relative stability over the five-year period, with minor fluctuations. While receivables turnover showed some variation, the collection period remained consistently within a narrow range, indicating a generally consistent approach to credit and collection policies.
- Average Receivable Collection Period
- The average receivable collection period was 57 days in both 2021 and 2022, demonstrating consistency in how quickly the company converts its receivables into cash during these years. A slight increase to 60 days was observed in 2023, suggesting a marginal lengthening in the time taken to collect receivables. This was followed by a decrease to 54 days in 2024, representing the shortest collection period within the observed timeframe. The period then increased slightly to 58 days in 2025, remaining close to the initial values from 2021 and 2022.
The observed fluctuations in the average collection period appear modest and do not indicate a significant shift in the company’s collection efficiency. The return towards the 57-58 day range in the later years suggests a stabilization after the brief deviation in 2023 and 2024.
- Relationship to Receivables Turnover
- The receivables turnover ratio generally moved inversely with the average collection period, as expected. A decrease in receivables turnover in 2023 corresponded with an increase in the average collection period, and the increase in turnover in 2024 coincided with a decrease in the collection period. This inverse relationship confirms the fundamental connection between these two metrics.
Overall, the analysis suggests a stable and predictable receivables management process. The minor variations observed do not appear to represent substantial changes in the company’s credit policies or the payment behavior of its customers.
Operating Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | ||||||
| Average receivable collection period | ||||||
| Short-term Activity Ratio | ||||||
| Operating cycle1 | ||||||
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Operating Cycle, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibited fluctuations over the five-year period. An initial increase in cycle length was followed by a period of contraction, then a subsequent lengthening. Overall, the operating cycle demonstrates a sensitivity to changes in both inventory processing and receivable collection efficiencies.
- Average Inventory Processing Period
- The average inventory processing period generally trended upward from 88 days in 2021 to 96 days in 2023. This indicates a lengthening in the time required to convert raw materials into finished goods and ultimately sell them. However, a decrease to 88 days was observed in 2024, followed by a slight increase to 90 days in 2025. This suggests potential improvements in inventory management in 2024, though these gains were not fully sustained.
- Average Receivable Collection Period
- The average receivable collection period remained relatively stable between 2021 and 2023, holding at 57 days, 57 days, and 60 days respectively. A notable decrease to 54 days occurred in 2024, indicating improved efficiency in collecting payments from customers. This improvement was partially offset by an increase to 58 days in 2025, suggesting a potential slowing in collection efforts.
- Operating Cycle
- The operating cycle increased from 145 days in 2021 to 156 days in 2023, reflecting the combined effect of lengthening inventory processing and a modestly increasing receivable collection period. A decrease to 142 days in 2024 was observed, driven by improvements in both inventory management and receivable collection. The cycle then lengthened again to 148 days in 2025, primarily due to a slight increase in the inventory processing period and a moderate increase in the receivable collection period.
The fluctuations in the operating cycle suggest that the company’s ability to efficiently manage its working capital is subject to change. The decrease in the operating cycle in 2024 is a positive sign, but the subsequent increase in 2025 warrants further investigation to determine the underlying causes and potential mitigation strategies.
Average Payables Payment Period
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Payables Payment Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited a generally decreasing trend from 2021 to 2023, followed by a period of relative stability. Simultaneously, payables turnover demonstrated an increasing trend initially, then stabilized.
- Average Payables Payment Period
- The average payables payment period decreased from 82 days in 2021 to 65 days in 2023, representing a reduction of 17 days over the two-year period. This indicates the company was, on average, taking less time to pay its suppliers. From 2023 to 2025, the period remained relatively consistent, fluctuating between 65 and 67 days. This suggests a stabilization of payment practices following the initial decline.
- Payables Turnover
- Payables turnover increased from 4.48 in 2021 to 5.58 in 2023, indicating the company was paying its suppliers more frequently. This increase aligns with the observed decrease in the average payables payment period. From 2023 to 2025, payables turnover experienced a slight decline, moving from 5.58 to 5.45. This suggests a marginal slowing in the rate at which the company paid its suppliers, but remained at a higher level than in 2021 and 2022.
- Relationship between Metrics
- The inverse relationship between the average payables payment period and payables turnover is evident. As the payment period decreased, payables turnover increased, and vice versa. The stabilization of the payment period from 2023 to 2025 corresponds with a stabilization in payables turnover, suggesting a consistent approach to supplier payments during this timeframe.
Overall, the company demonstrated improved efficiency in managing its payables from 2021 to 2023, followed by a period of maintained performance. The slight fluctuations in the later years do not appear to indicate a significant shift in payment strategy.
Cash Conversion Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | ||||||
| Average receivable collection period | ||||||
| Average payables payment period | ||||||
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | ||||||
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Cash Conversion Cycle, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
An examination of short-term operating activity reveals fluctuations in the components of the cash conversion cycle over the five-year period. The average inventory processing period exhibited an increasing trend from 88 days in 2021 to a peak of 96 days in 2023, before decreasing to 90 days in 2025. The average receivable collection period remained relatively stable between 57 and 60 days from 2021 to 2023, then decreased to 54 days in 2024, and increased slightly to 58 days in 2025. A notable decrease in the average payables payment period was observed from 82 days in 2021 to 67 days in 2022, followed by relative stability between 65 and 67 days for the remaining years.
- Average Inventory Processing Period
- The average inventory processing period increased over the initial two years of the period, suggesting a potential slowdown in inventory turnover. The subsequent decrease in 2024 and stabilization in 2025 may indicate improved inventory management practices or a change in sales patterns. The period remained elevated compared to the 2021 level.
- Average Receivable Collection Period
- The average receivable collection period demonstrated minimal change from 2021 to 2023, indicating consistent efficiency in collecting payments from customers. The reduction in 2024 suggests an improvement in collection efficiency, while the slight increase in 2025 may be attributable to timing differences or changes in customer payment terms.
- Average Payables Payment Period
- The most significant change occurred in the average payables payment period, with a substantial decrease from 2021 to 2022. This suggests the company took advantage of extended payment terms with suppliers or improved its payment processes. The period remained relatively consistent in the subsequent years, indicating a stable relationship with suppliers.
- Cash Conversion Cycle
- The cash conversion cycle increased from 63 days in 2021 to a high of 91 days in 2023, driven primarily by the increases in both the inventory processing and receivable collection periods. A decrease to 76 days in 2024 was observed, likely due to the reduction in the receivable collection period. The cycle increased again to 81 days in 2025, reflecting a combination of factors including a slight increase in the inventory processing period and the receivable collection period. Overall, the cycle demonstrates volatility, suggesting potential areas for operational improvement.